Organon & (US:OGN) Prnewswireยท2025-07-03 13:00Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1]. Group 1: Allegations and Impact - The complaint alleges that Organon's management provided overly positive statements while concealing critical information about the company's priorities, particularly regarding its debt reduction strategy after acquiring Dermavant [1]. - Following the revelation of these issues, Organon's regular quarterly dividend was reduced by 70%, leading to a significant drop in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a decline of over 27% in just one day [1]. Group 2: Class Action Details - Shareholders who purchased shares of Organon during the class period from October 31, 2024, to April 30, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for July 22, 2025 [2]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no cost or obligation to participate [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices, aiming to ensure companies adhere to responsible business practices [3].